SCHEMBL322945

SCHEMBL322945

Cc1cccc(COC(=O)N2C=Cc3ccccc3C2)c1C

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.35
MAPT P10636 2/20 0.35
HDAC3 O15379 1/20 0.34
GRIN2B Q13224 1/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.34
LMNA P02545 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HTT P42858 1/20 0.32
GAA P10253 1/20 0.32
P2RX4 Q99571 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
ATM Q13315 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
HSD17B3 P37058 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324798 0.92 GRIN2B (0.40) ALDH1A1MAPTHDAC3GRIN2BNPC1
SCHEMBL324429 0.87 HDAC3 (0.36) ALDH1A1MAPTHDAC3LMNANPC1
SCHEMBL323574 0.83 GRIN2B (0.41) ALDH1A1MAPTGRIN2BLMNANPC1
SCHEMBL324992 0.83 NPSR1 (0.37) HDAC3GRIN2BPTGDR2NPC1RAB9A
SCHEMBL324997 0.82 F13A1 (0.39) ALDH1A1HDAC3GRIN2BPTGDR2NPC1
SCHEMBL325479 0.82 RECQL (0.41) ALDH1A1MAPTPTGDR2NPC1RAB9A
SCHEMBL29493251 0.82 HDAC3 (0.41) ALDH1A1MAPTHDAC3GRIN2BLMNA
SCHEMBL15056964 0.82 HDAC3 (0.41) ALDH1A1MAPTHDAC3GRIN2BLMNA
SCHEMBL324263 0.82 L3MBTL1 (0.40) ALDH1A1MAPTHDAC3NPC1RAB9A
SCHEMBL322852 0.82 MMP1 (0.39) ALDH1A1MAPTHDAC3PTGDR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 ALDH1A1 2057/4885MAPT 4762/4885HDAC3 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.